

P. 2
PATENT

Attorney Docket No.: 10018.200-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Duffner et al

Confirmation No: 6134

Serial No.: 09/823,825

Group Art Unit: 1639

Filed: March 30, 2001

Examiner: Ponnaluri

For: Signal Sequence Trapping

RESPONSE TO RESTRICTION REQUIREMENTCommissioner for Patents
Washington, DC 20231

Sir:

This paper is filed in response to the Office Action mailed January 30, 2003 that made restriction and election of species requirements. Applicants were requested to elect one of four designated groups.

In response to these requirements, Applicants hereby elect the invention of group I, claims 1-4, 13, 15, 19-21, 29-30 and 39. Applicants also elect the following species:

- a) genomic DNA;
- b) *E. coli* host cell; and
- c) the beta-lactamase secretion reporter.

The species requirement appears to incorrectly require an election of a "secretion promoter" species instead of a "secretion reporter" species. Applicants have responded based on this assumed error, however, clarification by the Examiner is requested. Applicants hereby reserve the right to file continuing applications directed to the nonelected subject matter.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this response or application.

Respectfully submitted,

Date: February 26, 2003



Jason I. Garbell, Reg. No. 44,116
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097

Attorney Docket No.: 10018.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Duffner et al

Confirmation No: 6134

Serial No.: 09/823,825

Group Art Unit: 1639

Filed: March 30, 2001

Examiner: Ponnaluri

For: Signal Sequence Trapping

OFFICIAL**CERTIFICATE OF FACSIMILE TRANSMISSION FAX RECEIVED**Commissioner for Patents
Washington, DC 20231

FEB 27 2003

GROUP 1600

Sir:


I hereby certify that the attached correspondence comprising:

1. Response to Restriction Requirement

was sent to the United States Patent Office by telefax to the attention of Examiner Ponnaluri, fax number (703) 308-4242.

Respectfully submitted,

Date: February 26, 2003



Jason Garbell
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097